Clinical Proof of concept for a RNA-targeting Oligonucleotide for a Cystic fibrosis-F508del MEDication

Project Information

PRO-CF-MED

Grant agreement ID: 633545

DOI 10.3030/633545

Project closed

EC signature date 21 April 2015

Start date 1 May 2015

End date 31 December 2017

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 21 237 179,50

EU contribution € 5 997 139,00

Coordinated by

PROQR THERAPEUTICS NV
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (1)

PRO-CF-MED project website developed including project updates and patient ‘friendly’ section

Publications

Other (1)

QR-010 significantly improves CFTR function in nasal potential difference proof of concept study in subjects with CF homozygous for the F508del-CFTR mutation

Author(s): I Sermet-Gaudelus, D Nichols, JA Nick, C De Boeck, JP Clancy, GM Solomon, SM Rowe, JS Elborn, MA MAll, JA Bolognese, F Bouisset, W den Hollander, N Lamontagne, N Tomkinson, N Henig
Published in: 2016
Publisher: poster at the North American Cystic Fibrosis Conference

Peer reviewed articles (1)

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives

Author(s): Sabrina Noel, Bela Z Schmidt, Jeremy Haaf, Teresinha Leal
Published in: Clinical Pharmacology: Advances and Applications, Issue Volume 8, 2016, Page(s) 127-140, ISSN 1179-1438
Publisher: Dove Medical Press Ltd
DOI: 10.2147/CPAA.S100759

Intellectual Property Rights

Patent (1)

OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL

Application/Publication number: EP 13760133
Date: 2013-07-12
Applicant(s): PROQR THERAPEUTICS NV